The use of sulphydryl containing drugs and chelating agents to reduce renal irradiation during 203Hg chlormerodrin scintigraphy.
D000818:Animals; D002614:Chelating Agents / Q000627:therapeutic use*; D002717:Chlormerodrin; D003545:Cysteine / Q000627:therapeutic use / Q000633:toxicity; D004112:Dimercaprol / Q000627:therapeutic use / Q000633:toxicity; D004492:Edetic Acid / Q000627:therapeutic use; D007668:Kidney / Q000528:radiation effects; D007677:Kidney Function Tests; D008624:Mercaptoethylamines / Q000627:therapeutic use; D008628:Mercury / Q000378:metabolism; D008629:Mercury Isotopes / Q000009:adverse effects*; D011817:Rabbits; D011832:Radiation Injuries / Q000517:prevention & control*; D011877:Radionuclide Imaging / Q000009:adverse effects*; D013438:Sulfhydryl Compounds / Q000627:therapeutic use* / Q000633:toxicity*; D008063:Thioctic Acid / Q000627:therapeutic use / Q000633:toxicity; D013997:Time Factors
D002614:Chelating Agents; D008624:Mercaptoethylamines; D008629:Mercury Isotopes; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; D008063:Thioctic Acid; D002717:Chlormerodrin; D004492:Edetic Acid; D008628:Mercury; D003545:Cysteine